Bharat Biotech Limited Current Affairs, GK & News

Covaxin approved for emergency use in 2–18-year-olds

The Subject Expert Committee on Covid-19 has approved the “emergency use” of Bharat Biotech’s Covaxin vaccine for children aged between 2-18 years old. Key Points Phase-2 and Phase-3 trials of the Covaxin vaccine by Hyderabad-based Bharat Biotech on children below the age of 18 years in the months of September. Trial data was submitted to ..

Month: 

Category: 

Topics: 

SII’s Covishield gets emergency-use nod from DGCI

The Subject Expert committee that is advising the Drug Controller General of India (DCGI) recommended restricted Emergency Use Authorisation for COVISHIELD. COVISHIELD vaccine was developed by Serum Institute of India. Who manufactures COVISHIELD? The COVISHIELD the vaccine is developed by the University of Oxford and the British Pharmaceutical major Astra Zeneca. In India, the vaccine ..

Month: 

Category: 

Topics: 

Indigenously Developed ‘COVAXIN’ gets DCGI approval for Human Clinical Trials

The Drug Controller General of India (DCGI) has given approval for Phase I and Phase II human clinical trials for COVID-19 vaccine ‘COVAXIN’. In association with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV), COVAXIN is developed by Hyderabad based vaccine & bio-therapeutics manufacturer-Bharat Biotech.  At NIV Pune, the ..

Month: 

Category: 

Topics: 

Gagandeep Kang awarded Fellowship of the Royal Society (FRS), UK

Gagandeep Kang becomes first Indian woman scientist to be awarded Fellowship of the Royal Society (FRS), United Kingdom. Gagandeep Kang She is a clinician scientist, who is well known for her key role in development of Rotavac. She currently appointed as executive director of Translational Health Science and Technology Institute (THSTI), Faridabad, which is an ..

Category: 

Topics: